The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology Drug Updates: Biosimilars Seek Regulatory Approval in the U.S., Europe; Methotrexate Underused

Rheumatology Drug Updates: Biosimilars Seek Regulatory Approval in the U.S., Europe; Methotrexate Underused

February 16, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF
ajt/shutterstock.com

Image Credit: ajt/shutterstock.com

Biosimilars Receive Positive News

On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 If approved, Benepali can be used to treat rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis and plaque psoriasis. At present, no biosimilars of etanercept or subcutaneous anti-TNF biosimilars are available in the European market. If approved, Benepali will meet both of these criteria.

You Might Also Like
  • Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.
  • Rheumatology Drug Updates: Biosimilars Receive Positive News & More
  • Rheumatology Drug Updates
Explore This Issue
February 2016
Also By This Author
  • FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

On Nov. 25, 2015, Amgen submitted an application for marketing approval to the U.S. Food and Drug Administration (FDA) for ABP 501, its adalimumab biosimilar.2 The submission includes analytical, clinical and pharmacokinetic data. Phase 3 safety and comparative efficacy studies were performed for both moderate to severe plaque psoriasis and moderate to severe RA. The study results showed clinical equivalence to adalimumab, with safety and immunogenicity comparable with adalimumab. On Jan. 5, 2016, the FDA accepted this application for review.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Worldwide, Humira (adalimumab) sales were almost $12.5 billion in 2014. Humira patents expire in December 2016 in the U.S. and April 2018 in Europe.

Methotrexate Underused in U.S. for RA Patients

A recent analysis of U.S. methotrexate (MTX) use for RA was evaluated using Symphony Health Solutions’ anonymized patient-level claims data.3 Using ICD-9 codes, the researchers identified 35,640 RA patients who started oral MTX treatment in 2009. The study followed these patients to 2014. The data included switches from oral to subcutaneous MTX and/or biologics, timing of treatment changes and oral MTX or subcutaneous MTX dosing switches/addition, time or end of follow-up.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Forty-four percent of patients continued oral MTX alone through the end of the follow-up period (n=15,599). Forty-nine percent added or switched to a biologic agent (n=17,528). The median time before the addition of a biologic was 170 days, and 42% added a biologic within 90 days of oral MTX initiation. Only 7% switched from oral to subcutaneous MTX (within 534 days); 14% switched to oral MTX (within 90 days).

Overall, 71% of patients who switched from oral to subcutaneous MTX stayed on this treatment for about three years. Patients who added a biologic agent switched to a biologic after about 289 days. The mean time to change to a biologic agent was significantly longer (823 days, P<0.0001) for patients treated with subcutaneous MTX compared with those who received only oral MTX (170 days). This study showed that more than 40% of RA patients who initiated oral MTX treatment switched to or had a biologic added within 90 days after a median dose of 15 mg per week.

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: Approvals, Biosimilars, drug, FDA, Ibuprofen, Methotrexate, pregabalin, Rheumatoid arthritis, rheumatology, Safety, sarilumabIssue: February 2016

You Might Also Like:
  • Biosimilars Seek Regulatory Approval in the U.S. & Europe; Plus MTX Underused in the U.S.
  • Rheumatology Drug Updates: Biosimilars Receive Positive News & More
  • Rheumatology Drug Updates
  • Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.